Legal & Regulatory Updates

The Current Regulatory Landscape

Understanding the legal framework for hormone optimization requires separating several categories of compounds, each governed by different rules. Testosterone and other anabolic hormones are DEA-scheduled controlled substances. Peptides occupy a more complex space between research chemicals, compounded medications, and FDA-approved drugs. Supplements like DHEA and pregnenolone are legally sold over the counter under the Dietary Supplement Health and Education Act (DSHEA) of 1994, despite being steroid hormones.

The regulatory landscape has shifted dramatically since 2020. The reclassification of HCG as a biologic, FDA scrutiny of compounding pharmacies, evolving peptide category lists, and changing telehealth rules have all impacted how men access hormone optimization therapies. This is an area where staying informed is not optional. Compounds that are legally available through compounding pharmacies today may not be tomorrow, and vice versa.

The key regulatory bodies involved are the FDA (Food and Drug Administration), which regulates drug approval, compounding, and safety; the DEA (Drug Enforcement Administration), which schedules controlled substances; state medical boards, which regulate prescribing practices; and state pharmacy boards, which regulate compounding pharmacies. All four can independently affect your access to specific compounds.

FDA Peptide Categories

The FDA maintains several lists that determine whether a compound can be legally compounded by pharmacies. The most important for the peptide community are the “Bulk Drug Substances” lists under Section 503A (traditional compounding) and Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.

Category 1: FDA-Approved Peptides

These have gone through the full FDA approval process and are available as branded pharmaceuticals. Examples include tesamorelin (Egrifta), semaglutide (Ozempic/Wegovy), and gonadorelin (Factrel). They can be prescribed and dispensed through standard pharmacies and can also be compounded under certain shortage conditions.

Category 2: Compoundable Peptides

These appear on the FDA's bulk drug substance lists and can be legally compounded by 503A and 503B pharmacies with a valid prescription. The list changes periodically. As of early 2026, compounds like CJC-1295 (without DAC), ipamorelin, and PT-141 (bremelanotide) remain compoundable in many jurisdictions, though their status is subject to ongoing FDA review.

Category 3: Research Use Only

Peptides not approved by the FDA and not on bulk drug substance lists exist in the “research chemical” space. They can be manufactured and sold labeled “for research purposes only, not for human consumption.” BPC-157 and TB-500 currently fall into this category in the United States. Purchasing them is legal, but selling them for human use is not. The practical enforcement of this distinction has historically been limited, though FDA enforcement actions have increased since 2024.

Compounding Pharmacy Rules

Compounding pharmacies operate under two primary regulatory frameworks. Section 503A pharmacies are traditional compounders that prepare medications based on individual patient prescriptions from licensed providers. They must comply with state pharmacy board regulations and can compound from bulk drug substances that are either on the FDA's approved list, have a USP/NF monograph, or are components of an FDA-approved drug.

Section 503B outsourcing facilities can prepare larger batches without individual prescriptions and must register with the FDA, follow current Good Manufacturing Practices (cGMP), and submit to FDA inspections. They face stricter oversight but can distribute more widely. The 503B pathway has become increasingly important for peptide access as it provides a higher quality assurance framework.

The key risk for consumers is that compounding pharmacy regulations create a patchwork of availability. A peptide that can be legally compounded in Texas may not be compoundable in New York. State pharmacy boards interpret federal guidelines differently, and some states have enacted additional restrictions on specific compounds. Always verify that your compounding pharmacy is licensed in your state and that the specific compound you are ordering is legally compoundable there.

Telehealth TRT Regulations

The COVID-19 pandemic produced emergency telehealth flexibilities that allowed controlled substances, including testosterone, to be prescribed via telemedicine without an in-person evaluation. As these flexibilities have been modified, the rules for telehealth prescribing of controlled substances have evolved through multiple DEA rulemaking cycles.

As of 2026, the DEA has established a framework that generally allows initial prescribing of Schedule III-V controlled substances via telemedicine for a limited supply, with an in-person evaluation required within a specified timeframe (typically 180 days) for continued prescribing. However, the specifics continue to evolve through rulemaking, and state-level regulations add additional requirements in many jurisdictions.

For TRT specifically, most established telehealth clinics require initial bloodwork, a medical history review via video consultation, and periodic follow-up labs. The legitimate clinics operate with licensed physicians, maintain proper DEA registrations, and use licensed pharmacies for dispensing. The red flags include clinics that prescribe without any bloodwork, guarantee specific outcomes, or ship controlled substances from out-of-country pharmacies.

State medical boards also have jurisdiction over telehealth prescribing. Some states require the prescribing physician to be licensed in the patient's state of residence. Others participate in interstate compacts that allow broader telehealth access. Check your state medical board's website for current telehealth prescribing rules.

State-by-State Variations

While federal law provides the baseline, individual states can and do impose additional restrictions on hormone therapy access, compounding pharmacy operations, and telehealth prescribing. This creates significant variation in what is practically available depending on where you live.

States with generally more permissive frameworks for hormone optimization access include Texas, Florida, Arizona, and Tennessee. These states tend to have active compounding pharmacy industries, established telehealth-friendly regulations, and state medical boards that are less restrictive toward optimization-focused prescribing.

States with more restrictive approaches include New York, California (for certain compounds), and several northeastern states that have enacted stricter compounding pharmacy oversight, additional telehealth requirements, or more conservative medical board positions on optimization-focused prescribing.

The practical impact is that a man in Texas may have straightforward access to a compounded CJC-1295/ipamorelin protocol prescribed via telemedicine, while a man in New York may need to find an in-state provider, use a locally licensed pharmacy, and navigate additional regulatory requirements for the same protocol. Neither situation is inherently better or worse for patient safety, but the access and convenience differences are real.

International Status

Hormone and peptide regulations vary dramatically by country. In many countries outside the United States, testosterone is available without a prescription or with minimal medical oversight. In others, it is more tightly controlled than in the US.

The United Kingdom classifies anabolic steroids as Class C controlled drugs. Possession for personal use is legal, but supply and distribution are criminal offenses. Peptides are generally unregulated for personal use but cannot be marketed as medicines. The UK's approach creates a somewhat permissive environment for personal use while restricting commercial activity.

Australia has one of the more restrictive frameworks, classifying testosterone and many peptides as prescription-only medications with significant enforcement against importation for personal use. Canada regulates testosterone as a prescription drug but has a more accessible compounding pharmacy infrastructure for peptides. Mexico allows over-the-counter purchase of many hormone compounds that require prescriptions in the US and Canada.

For international readers, the critical point is that this site's regulatory information is US-centric unless otherwise noted. Always verify the legal status of any compound in your specific country before purchasing, importing, or using it.

What Is Changing in 2026

Several regulatory developments are actively unfolding that may impact peptide and hormone access:

• Semaglutide compounding status: The FDA's declaration regarding semaglutide shortage status continues to evolve, directly impacting whether compounding pharmacies can produce compounded semaglutide. When shortages are declared resolved, compounding access narrows significantly.
• Peptide bulk drug substance nominations: Multiple industry groups and patient advocacy organizations have submitted nominations for peptides to be added to the FDA's bulk drug substance lists, which would formalize their compounding legality. Review of these nominations is ongoing.
• DEA telehealth rulemaking: The DEA continues to refine its telehealth prescribing framework for controlled substances. Additional rulemaking is expected that may affect initial and ongoing telehealth TRT prescribing requirements.
• State-level telehealth legislation: Multiple states are considering legislation that would either expand or restrict telehealth prescribing for hormone therapies. Monitor your state legislature for relevant bills.

Protecting Your Access

Regulatory changes can disrupt access to compounds you rely on. Here are practical steps to protect continuity of care:

• Establish a relationship with a licensed provider. Having a documented patient-provider relationship with comprehensive medical records supporting your treatment makes it much easier to maintain access when regulations change. Providers can adapt protocols, switch compounds, or provide medical necessity documentation.
• Use licensed, reputable pharmacies. Compounds from regulated pharmacies come with quality assurance, legal protection, and continuity of supply. Research chemical suppliers may be cheaper but offer none of these protections.
• Maintain comprehensive bloodwork records. A documented history of pre-treatment levels, treatment response, and ongoing monitoring demonstrates medical necessity and supports continued prescribing regardless of regulatory changes.
• Stay informed. Follow the regulatory developments covered on this page. Join patient advocacy groups that lobby for continued access to optimization therapies. The Alliance for Pharmacy Compounding and various peptide therapy advocacy organizations actively engage with regulators.
• Have backup plans. If your primary compound becomes unavailable, know what alternatives exist. If your peptide protocol includes compounds in the research chemical category, understand that their availability could change with little notice.

Frequently Asked Questions